ArticlePlastic and reconstructive surgery. Global open2026
Process-dependent Analytical Differences Among Commercial Botulinum Neurotoxin Type A Formulations.
Article in Plastic and reconstructive surgery. Global open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Manufacturing-related factors may influence measurable compositional and functional characteristics of botulinum neurotoxin type A (BoNT/A) formulations beyond structural subtype equivalence. However, comparative analytical data on commercially available products remain limited. Methods: Commercial-scale BoNT/A formulations were subjected to analytical and biofunctional evaluation. Residual nucleic acid clearance was characterized across multiple production batches of letibotulinumtoxinA to assess purification robustness within that manufacturing process. Total neurotoxin protein content was measured by enzyme-linked immunosorbent assay (ELISA), and biological potency was determined using the mouse LD Results: Residual nucleic acid removal in letibotulinumtoxinA exceeded 99.9% across the evaluated batches, indicating efficient impurity clearance within the assessed manufacturing process. In the mouse LD Conclusions: This study provides an analytical characterization of commercially available BoNT/A formulations with respect to impurity clearance and protein-normalized biological activity. The findings support the relevance of manufacturing quality to product characterization, but do not establish clinical superiority, product preference, or direct implications for clinical outcomes. Further clinical and translational investigation is required to determine the potential relevance of these observations in practice.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.